BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nishida T, Sato S, Ozaka M, Nakahara Y, Komatsu Y, Kondo M, Cho H, Hirota S, Kagimura T, Kurokawa Y, Kitagawa Y; STAR ReGISTry Investigators. Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world. Gastric Cancer 2022;25:956-65. [PMID: 35672526 DOI: 10.1007/s10120-022-01310-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Campora M, Paudice M, Gambella A, Comandini D, Parente P, Sbaraglia M, Dei Tos AP, Grillo F, Mastracci L. Counting mitoses in gastrointestinal stromal tumours (GISTs): variable practices in the real-world setting and their clinical implications. Virchows Arch 2023;482:589-94. [PMID: 36416965 DOI: 10.1007/s00428-022-03454-w] [Reference Citation Analysis]
2 Imatinib. Reactions Weekly 2022;1926:255-255. [DOI: 10.1007/s40278-022-24533-x] [Reference Citation Analysis]
3 Wang F, Zheng H, Li J, Li P, Zheng C, Chen Q, Huang C, Xie J. Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features. Radiol med 2022;127:1085-1097. [DOI: 10.1007/s11547-022-01549-7] [Reference Citation Analysis]